Lexeo Therapeutics financials
$3.42+8.92%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — |
| Operating income | -$109.3M | -$105.8M | -$68.5M |
| Net income | -$100.0M | -$98.3M | -$66.4M |
| Net margin | — | — | — |
| Diluted EPS | $-1.86 | $-3.09 | $-12.40 |
| EBITDA | -$109.0M | -$105.5M | -$68.2M |
| Operating cash flow | -$98.6M | -$81.2M | -$59.5M |
| Free cash flow | -$99.0M | -$81.6M | -$59.6M |
| Diluted shares | 53.6M | 31.8M | 5.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $63.0M | $35.0M | $121.5M |
| Short-term investments | $118.8M | $86.5M | $0.00 |
| Total debt | $845.0K | $1.4M | $1.8M |
| Total assets | $268.7M | $146.9M | $139.8M |
| Total liabilities | $22.0M | $30.1M | $26.3M |
| Shareholders' equity | $246.7M | $116.8M | $113.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology